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Abstract
Introduction: Syntenin is a scaffolding-PDZ domain-containing protein. Although it is reported that syntenin is
associated with melanoma growth and metastasis, the possible role of syntenin in breast cancer has not been well
elucidated. The present study investigated the expression and function of syntenin in breast cancer.
Methods: Real-time polymerase chain reaction (PCR) and Western blots were used to determine the mRNA and
protein expression of syntenin. With a combination of overexpression and RNA interference, the effect of syntenin
on migration, invasion, and ERK1/2 activation was examined in breast cancer cell lines. The effect of syntenin
in vivo was assessed with an orthotropic xenograft tumor model in BALB/c nu/nu mice. In addition, the expression
level of syntenin in clinical breast cancer tissues was evaluated with immunohistochemistry. The Kaplan-Meier
survival curve was used to evaluate patient survival, and the Cox proportional hazards model was used for
multivariate analysis.
Results: Our study showed that syntenin expression was upregulated in high-metastasis breast cancer cell lines and
breast cancer tissues. Overexpression of syntenin in breast cancer cells promoted cell migration and invasion in vitro.
Moreover, overexpression of syntenin promoted breast tumor growth and lung metastasis in vivo. We further showed
that activation of integrin b1 and ERK1/2 was required for syntenin-mediated migration and invasion of breast cancer
cells. The correlation between syntenin expression and tumor size (P = 0.011), lymph node status (P = 0.001), and
recurrence (P = 0.002) was statistically significant. More important, syntenin expression in primary tumors was
significantly related to patients’ overall survival (OS; P = 0.023) and disease-free survival (DFS; P = 0.001). Its status was an
independent prognostic factor of OS (P = 0.049) and DFS (P = 0.002) in our cohort of patients.
Conclusions: These results suggest that syntenin plays a significant role in breast cancer progression, and it
warrants further investigation as a candidate molecular marker of breast cancer metastasis and a potential
therapeutic target.
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Introduction
Breast cancer is the most common malignancy in
women, and metastasis is the major cause of mortality
[1]. Although many molecules have been implicated in
breast cancer occurrence and progression, the detailed
mechanism is still not completely understood. Syntenin
is a scaffolding-PDZ domain-containing protein involved
in multiple biologic functions, including syndecan bind-
ing and recycling, receptor clustering, protein trafficking,
signal transduction, and regulation of the transcription
factor Sox4 proteasomal degradation [2-7]. The PDZ
domains of syntenin bind to multiple peptide motifs with
low-to-medium affinity [8,9], are essential for assembly
and organization of diverse cell-signaling processes
occurring at the plasma membrane [6,10]. More recently,
many reports described interactions between syntenin
and a large number of proteins, including class B ephrins,
pro-transforming growth factor-a, phosphotyrosine
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phosphatase-D, neurofaschin, neurexin, schwannomin
(also known as merlin), IL-5 receptor, various glutamate
receptor subtypes, the syndecan family of heparan sulfate
proteoglycans, and ubiquitin [6,11], indirectly implicating
its role in a variety of cellular processes.
Extensive studies have shown that syntenin is upregulated
in several cancer cells and tissues and may regulate tumor
cell invasion and metastasis [3,12-14]. Boukerche and col-
leagues [3,15] found that syntenin could increase FAK, JNK
and p38 MAP kinase activity, as well as activation of
nuclear factor-kappaB (NF-B), all of which play an impor-
tant role in syntenin-mediated anchorage-independent
growth and motility in melanoma. In contrast to the obser-
vations in melanoma, overexpression of syntenin resulted
in increased phosphorylation of AKT S473 and extracellu-
lar signal-regulated kinase ERK1/2 in HEK 293T cells [13].
Moreover, inhibition of p38 or JNK MAPK did not have
any effect on syntenin-induced invasion in HEK 293T cells
[13]. This discrepancy might be explained by cell type-
specific action of syntenin. The diversity of syntenin-
interaction partners also suggests that syntenin may have
flexible cell-type-specific roles.
Although the function of syntenin in melanoma has
been partially revealed, little is known about the expres-
sion of syntenin and what the molecular mechanisms are
in breast cancer. In the present study, we found an ele-
vated expression of syntenin in high-metastasis breast can-
cer cell lines and breast cancer tissues. Moreover, forced
syntenin overexpression promoted cell migration and cell
invasion, suggesting a possible role of syntenin in meta-
static spreading of breast cancer cells. Consistent with
in vitro results, we observed that syntenin overexpression
promoted breast tumor growth and lung metastasis in
vivo. We further showed that syntenin-mediated migration
and invasion of breast cancer cells required the activation
of integrin b1 and ERK1/2. The correlation between synte-
nin expression and tumor size, lymph node status, and
recurrence was statistically significant. More important,
immunohistochemistry staining showed that the expres-
sion level of syntenin in primary tumors was significantly
related to patient survival in our cohort of patients.
Materials and methods
Reagents
Antibodies specific for syntenin (sc-100336) and GAPDH
were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA, USA). Antibodies against ERK1/2, phospho-
ERK1/2, JNK, phospho-JNK, p38, and phospho-p38 were
obtained from Cell Signaling Technology (Beverly, MA,
USA). Secondary antibodies, HRP-conjugated Goat anti-
Mouse IgG, Goat anti-Rabbit IgG, and anti-integrin b1
(MAB2079Z for Western blot and MAB1959 for func-
tional blocking) were obtained from Millipore (Billerica,
MA, USA). MAB2079Z is specific for active conformation
of human integrin b1.
Cell-culture media and all supplements were pur-
chased from Invitrogen (Basel, Switzerland). All reagents
for gel electrophoresis were obtained from Bio-Rad
(Reinach, Switzerland). U0126 was purchased from
Sigma Chemical Co. (St. Louis, MO, USA). Matrigel was
purchased from BD Biosciences (San Diego, CA, USA).
Cell culture
Human breast cancer cell lines MCF7, ZR-75-1, ZR-75-30,
MDA-MB-468, MDA-MB-435, and MDA-MB-231 were
purchased from the American Type Culture Collection
(Manassas, VA, USA). The highly metastatic MDA-MB-
231HM cell line was established by subclone-selection
procedure in our institute, and its establishment was
described previously [16,17]. The MDA-MB-231HM and
MDA-MB-435 cell lines have high metastatic potential to
the lung. MDA-MB-231, MDA-MB-231HM, MDA-MB-
468, and MDA-MB-435 cells were grown in Leibovitz L-
15 medium; ZR-75-1 and ZR-75-30 cells were maintained
in RPMI 1640 medium; and MCF-7 cells were maintained
in DMEM medium. All media were supplemented with
10% fetal bovine serum (FBS), penicillin (100 units/ml),
and streptomycin (0.1 mg/ml). All cells were incubated at
37°C in a humidified 5% CO2 atmosphere.
Real-time quantitative PCR
Total RNA was extracted by using TRIzol reagent (Invitro-
gen, Carlsbad, CA, USA), and reverse transcription was
performed with a PrimeScript RT reagent Kit (Takara Bio-
technology, Dalian, China). Gene-specific primers for
human syntenin and GAPDH were generated by Sangon
Biotech (Shanghai) Co., Ltd. The primer sequences were
as follows: human syntenin (forward primer, 5’- TTCT
GCTCCTATCCCTCACG-3’ and reverse primer, 5’-
CCAGTTACAGGAGCCACCAT -3’), human GAPDH
(forward primer, 5’- TGCCAAATATGATGACATCAA-
GAA-3’ and reverse primer, 5’-GGAGTGGGTGTCG
CTGTTG-3’). The iCycler and iQ real-time PCR (Bio-Rad,
Hercules, CA, USA) and SYBR-Green PCR Master Mix
(Toyobo, Osaka, Japan) were used for amplification and
detection. The qPCR condi¬tions were as follows: 95°C for
5 minutes; and 95°C for 30 seconds, 60°C for 30 seconds,
and 72°C for 30 seconds for 39 additional cycles. Data
were recorded and analyzed by using the real-time PCR
analysis software Bio-Rad iQ5. All experiments were
repeated thrice, and the mRNA levels of each gene were
normalized to that of GAPDH as an internal control.
Western blot
Cell lysates were prepared in RIPA buffer with protease
inhibitors (complete mini protease inhibitor; Roche) and
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phosphatase inhibitor cocktail (Sigma-Aldrich). The
lysates were then clarified by centrifugation at 12,000 g
for 10 minutes at 4°C. Protein concentration was mea-
sured with the BCA assay (Thermo Scientific). Equivalent
amounts of protein were subjected to SDS-PAGE analy-
sis. Immunoblotting was performed by using standard
methods. Quantification of the protein was conducted by
the Image Analyzer LAS-3000 (FujiFilm Life Science,
Tokyo, Japan). The image was analyzed with densitome-
try. Each sample was normalized to GAPDH.
Cloning and stable overexpression of syntenin
The coding sequence of syntenin (897 bp) was cloned
from normal human cDNA. We cloned syntenin into the
pCDH-CMV-MCS-EF1-PURO expression vector (System
Biosciences). Constructs were confirmed by sequencing.
Production of the lentiviral particles was carried out
according to the manufacturer’s protocol. MDA-MB-231
cells were infected with the lentiviral particles according to
the manufacturer’s protocol. The empty vector was pack-
aged as a negative control. Stable transfectants were
selected and cultured in medium containing 3 µg/ml
puromycin.
Stable RNA interference against syntenin
We designed short-hairpin RNA molecules targeted
against sites beginning at nucleotides 262 and 622 of syn-
tenin. The following oligonucleotides were synthesized
(Sangon, Shanghai):









Oligonucleotides were annealed and inserted into
digested pLKO.1-TRC Cloning Vector plasmid. Produc-
tion of the lentiviral particles was carried out according to
the manufacturer’s protocol. MDA-MB-231HM cells were
infected with lentivirus particles containing the shRNA,
and stable transfectants were selected and cultured in
medium containing 3 µg/ml puromycin. The pLKO.1-
scramble shRNA plasmid was packaged as a negative con-
trol. The digested pLKO.1-TRC Cloning Vector plasmid,
packaging plasmid, pCMV-dR8.s2 dvpr, and envelope
pCMV-VSVG were purchased from Addgen (Cambridge,
MA, USA).
Scratch assay
Cells were seeded in 60-mm culture dishes at 1 × 105
cells/dish. A scratch through the central axis of the plate
was gently made by using a pipette tip. Migration of the
cells into the scratch was observed at time points of 24
and 48 hours.
Migration and invasion assay
Migration assay and invasion assay were conducted with a
24-well cell-culture chamber by using inserts with 8-μm
pores (Corning Costar). The breast cancer cell lines were
suspended in L-15 medium without FBS at 1× 105/ml
(migration) or 1× 106/ml (invasion), and 0.1 ml of the sus-
pension was added in triplicate to the inserts. L-15 med-
ium with 10% FBS was added into the lower chamber.
After a 4-hour (migration) or 36-hour (invasion) incuba-
tion at 37°C, the cells on the lower surface of the mem-
brane were stained with Giemsa stain and counted with
microscopy in five different fields (200×).
Animal experiments
The animals used in this study were 4- to 6-week-old
athymic female BALB/c nu/nu mice, which were provided
by Shanghai Institute of Materia Medica, Chinese Acad-
emy of Science. For mammary-fat-pad tumor assays, cells
were harvested by trypsinization, washed twice in PBS,
and counted. Cells were then resuspended (107 cells/ml)
in a 1:1 ratio of PBS and gelatinous protein (Matrigel).
Mice were anesthetized, a small incision was made to
reveal the mammary gland, and 106 cells were injected
directly into the mammary fat pad. The incision was
closed with wound clips, and primary tumor outgrowth
was monitored weekly by taking measurements of the
tumor length (L) and width (W). The animals were killed
and autopsies performed 6 weeks after tumor inoculation.
The tumor volumes were calculated by using the following
formula: volume = 0.52 × width2 × length. Metastasis for-
mation was assessed with microscopic observation of the
lung tissue slices. All animal experiments were carried out
with approval from the Shanghai Medical Experimental
Animal Care Commission, Fudan University.
Immunohistochemistry
Immunohistochemistry (IHC) staining of syntenin was
performed on formalin-fixed, paraffin-embedded sec-
tions from 239 patient tumor samples with known clini-
cal history (Table 1). Informed-consent forms were
obtained from all the patients. This study was approved
in advance by the Institutional Review Board of the
Cancer Hospital, Fudan University. Tumor sections were
incubated in a 1:100 dilution of anti-syntenin antibody
and a 1:50 dilution of anti-CD31 antibody. Negative
control consisted of phosphate-buffered saline instead of
primary antibody. Antibody sensitivity and specificity were
verified by IHC staining on formalin-fixed, paraffin-
embedded tumors formed by syntenin-overexpression and
syntenin-knockdown cells. Tumors formed by 231-SYN
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were used as positive controls in IHC staining of human
breast cancer tissues.
Negative control showed no brown staining, and positive
control showed specific staining with little or no back-
ground staining, indicating a successful IHC. Multiple
microscopic fields (200×) of each tumor section were ana-
lyzed. The results were read semiquantitatively by two
independent investigators, who were blinded to the patient
outcomes. Discrepancies between the two observers were
reviewed jointly to reach consensus.
The intensity of syntenin immunohistochemistry was
estimated and graded in a four-step scale as not stained
(−), slightly stained (+), moderately stained (++), or inten-
sely stained (+++). The results were classified into two
categories: positive (intensely stained or moderately
stained, 20% or more than 20% positive cells) and negative
(slightly stained or not stained, less than 20% of positive
cells).
Statistical analysis
ANOVA and Student t tests were used to determine the
statistical significance of differences between experimental
groups. The Kaplan-Meier method was used to analyze
breast cancer patient cumulative survival rate. Cox propor-
tional hazards model was used to analyze the independent
prognostic factor for breast cancer. Values of P<0.05 were
considered statistically significant. Statistical analysis and
graphs were created with GraphPad Prism (Graph-Pad
Software, San Diego, CA, USA).
Results
Expression of syntenin in high-metastasis breast cancer
cell lines and breast cancer tissues
We performed real-time PCR and Western blots to inves-
tigate the mRNA and protein expression levels of syntenin
in human breast cancer cell lines. As shown in Figure 1A
and 1B, MDA-MB-231HM cells had higher syntenin
expression than their parent cells and low-invasive cells,
such as MCF-7, ZR-75-1, ZR-75-30, and MDA-MB-468.
Meanwhile, the high-metastatic-potential cell line MDA-
MB-435 also had higher expression of syntenin than did
low-invasive cell lines. These findings suggest a potential
correlation between syntenin expression and the meta-
static ability of breast cancer cell lines.
Next, we confirmed that syntenin mRNA and protein
were also notably higher in breast carcinoma compared
with that in corresponding paracarcinoma tissues in 27
paired breast cancer samples (Figure 1C, D, and Addi-
tional file 1, Figure S1).
Syntenin overexpression promotes migration and
invasion of breast cancer cells in vitro
To quantify the direct contribution of syntenin in breast
cancer, we generated a 231-SYN cell line, which stably
overexpressed syntenin in MDA-MB-231 cells with a len-
tivirus-mediated system. A control cell line carrying
empty vector was also obtained and termed 231-VEC.
The overexpression was verified with real-time PCR
(Additional file 1, Figure S2A) and Western blot (Addi-
tional file 1, Figure S2B). Meanwhile, we generated
MDA-MB-231HM cells stably expressing syntenin
shRNA. Two independent sites were targeted, beginning
at nucleotide 262 and 622, to generate 231HM-262 cells
and 231HM-622 cells, respectively. The negative control
expressing scrambled shRNA was named 231HM-VEC.
The efficiency of knockdown was determined with real-
time PCR (Additional file 1, Figure S2C) and Western
blot (Additional file 1, Figure S2D).
Scratch assay and Transwell migration assay were per-
formed to test whether syntenin expression influences
the migratory behavior of cells. The 231-SYN cells exhib-
ited greatly enhanced migration ability compared with
either the MDA-MB-231 or 231-VEC cells (P < 0.001,
Figure 2A and 2C). Consistent results were observed in
MDA-MB-231HM cells (P < 0.001, Figure 2B and 2D).
Table 1 Clinicopathologic characteristics of the patients
Syntenin expression
Negative (n = 151) Positive (n = 88) P value
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We further investigated the role of syntenin in cell inva-
sion by using an invasion assay coated with Matrigel, and
found that syntenin overexpression also promotes breast
cancer cell invasion (P < 0.01; Figure 2E and 2F). These
results indicated that syntenin was involved in breast
cancer cell migration and invasion.
Syntenin overexpression promotes tumor growth and
lung metastasis in vivo
To determine whether syntenin could promote tumor
growth and accelerate metastasis in vivo, we used orthoto-
pic xenograft tumor models in the nude mice. As shown
in Figure 3A, 231-SYN cells formed larger tumors than
control 231-VEC cells (P < 0.01). Consistent results were
obtained by mammary fat pad implantation of 231HM-
VEC, 231HM-262, and 231HM-622 (P < 0.01; Figure 3B).
These results showed that syntenin overexpression could
promote tumor growth in vivo.
The number of lung metastatic nodules was counted
to determine whether the overexpression of syntenin in
breast cancer cells could enhance lung metastasis in
vivo. Hematoxylin-eosin (HE) stain was used to detect
the lung metastasis. As shown in Figure 3C, 231-SYN
cells led to more metastatic nodules than did the vector
Figure 1 Syntenin expression is upregulated in high-metastasis breast cancer cell lines and breast cancer tissues. (A) Real-time PCR
analysis of syntenin mRNA expression in breast cancer cell lines. (B) Western blots show the protein expression level of syntenin in breast
cancer cell lines. (C) Comparison of syntenin mRNA expression in 27 paired carcinomas (CARs) and paracarcinomas (PARA-CARs). Results
represent mean ± SD (P < 0. 01). (D) Representative Western blots results show that carcinoma significantly elevated syntenin expression
compared with paracarcinoma. The remaining samples results are showed in Additional file 1, Figure 1S. Relative mRNA levels were normalized
to GAPDH mRNA. Protein loading was monitored with immunoblot by using GAPDH antibodies.
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Figure 2 Effect of syntenin on breast cancer cell migration and invasion in vitro. (A, B) Cell migration assessed by scratch assay.
Representative area of cells at 48 hours after scratch assay is shown. (C, D) Migration assay. (E, F) Invasion assay. (C, E) Overexpression of
syntenin promoted breast cancer cell migration (C) and invasion (E). (D, F) The migrated or invaded cells were significantly reduced after
syntenin knockdown in MDA-MB-231HM cells. Cells were plated on noncoated or gelatinous protein (Matrigel)-coated filters for migration or
invasion assay, respectively. Cells that migrated or invaded through the pores in the filter were fixed, stained, and counted in five random fields
visualized with microscopy (200×). Data represent mean ± SD of three independent experiments performed in triplicate. **P < 0.01; ***P < 0.001.
Yang et al. Breast Cancer Research 2013, 15:R50
http://breast-cancer-research.com/content/15/3/R50
Page 6 of 13
Figure 3 Syntenin overexpression promotes breast tumor growth and lung metastasis in vivo. (A) Overexpression of syntenin promoted
breast tumor growth in nude mice (P < 0.01). (B) Volumes of tumors formed by syntenin-knockdown cells were significantly smaller than
control. Bars, SEM. Five mice in each group were used in this study. (C, D) Hematoxylin-eosin (HE) was used to examine the number of lung
metastasis (200×). Quantification of average metastasis number of per lung (n = 5). (E, F) Immunohistochemistry examination of CD31 for
microvessels in the final week of xenografts (200×). Quantification of average microvessel density per xenografts (n = 5). *P < 0.05.
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control cells (P < 0.05). Similarly, mice injected with the
231HM-262, 231HM-622 cells exhibited fewer pulmon-
ary metastatic nodules than did those injected with con-
trol cells (Figure 3D). These data demonstrate that
syntenin overexpression could promote breast cancer
cells metastasis to the lung. All the primary tumors
were evaluated by pathologic examination.
We next examined whether syntenin expression
affects angiogenesis. The results showed that microves-
sel density was significantly increased in tumors formed
by syntenin-overexpressing cells and decreased in
tumors formed by syntenin-knockdown cells (Figure 3E
and 3F). These data suggest that syntenin could enhance
tumor growth by promoting blood vessel formation.
Elevated syntenin expression induces integrin b1 and
ERK1/2 MAPK activation
To investigate the molecular mechanism by which synte-
nin induces cell migration and invasion in breast cancer
cells, we analyzed the effect of syntenin on MAPK activa-
tion. As shown in Figure 4A, knockdown of syntenin in
MDA-MB-231HM cells significantly reduced the phos-
phorylation levels of ERK1/2. In contrast, overexpression
of syntenin in MDA-MB-231 cells increased ERK1/2
phosphorylation (Figure 4B). However, either overexpres-
sion or knockdown of syntenin had no effect on JNK and
p38 MAPK activation (Figure 4A and 4B). These results
suggest that syntenin overexpression induced ERK1/2
MAPK activation in breast cancer cells.
We further investigated how syntenin activates ERK1/2
at the plasma membrane. Activation of the ERK1/2 cas-
cade is mostly initiated at membrane receptors, such as
receptor Tyr kinases (RTKs), G protein-coupled receptors
(GPCRs), integrins, ion channels, and so on. Previous
study showed that syntenin positively regulates the ILK
adaptor function for the assembly of integrin b1/IPP sig-
naling complexes, which activate integrin signaling path-
ways, including AKT, ERK1/2, and Rac1, in breast cancer
cells [18]. Additionally, a study reported that syntenin
could assemble multimeric integrin b1 signaling com-
plexes to activate FAK in response to FN in MDA-MB-
231 cells [19]. As shown in Figure 4A and 4B, we found
that knockdown of syntenin in MDA-MB-231HM cells
significantly reduced active integrin b1 expression,
whereas overexpression of syntenin in MDA-MB-231
increased active integrin b1 expression.
We next determined whether syntenin-induced altera-
tions of integrin b1 expression are responsible for ERK1/2
phosphorylation. We found that blocking integrin b1 sig-
naling by using a function-blocking antibody diminished
both active integrin b1 expression and syntenin-induced
ERK1/2 phosphorylation (Figure 4C). These results suggest
that integrin b1 expression was involved in syntenin-
induced ERK activation.
Inhibition of MEK/ERK pathway blocks syntenin
overexpression-induced cell migration and invasion
Further to investigate the role of ERK1/2 activation in
migration and invasion induced by syntenin overexpres-
sion, 231-SYN cells were treated with ERK1/2 inhibitors
(U0126) for 2 hours. 231-VEC cells were treated with
DMSO as a control. Remarkably, cells treated with U0126
significantly blocked ERK1/2 activation (Figure 4D) and
the induction of migration and invasion by syntenin over-
expression (Figure 4E and 4F). The data reveal an essential
role for ERK1/2 MAPK signaling in syntenin-induced
migration and invasion in 231-SYN cells.
Syntenin expression is correlated with breast cancer
patient survival
To validate the antibody used in immunohistochemistry
(IHC) staining, we performed IHC staining of paraffin-
embedded tumors formed by 231-VEC, 231-SYN, 231HM-
VEC, 231HM-262, and 231HM-622 cells. The results
showed that tumors formed by 231-SYN and 231HM-VEC
cells were intensely stained, whereas tumors formed by
231-VEC, 231HM-262, and 231HM-622 cells were weakly
stained or not stained (Figure 5A). These results are consis-
tent with the real-time PCR and Western blot results, and
reveal that the antibody used in IHC staining was sensitive
and specific.
To determine whether syntenin expression in primary
tumor tissues is associated with clinical characteristics
(Table 1), we performed immunohistochemistry staining
on samples from 239 patients. Paracarcinoma did not
show syntenin immunoreactivity (Figure 5A). Representa-
tive images of syntenin-positive and -negative staining are
presented in Figure 5A. As shown in Table 1, 88 (36.8%)
samples were syntenin positive in our cohort of patients.
The correlation between syntenin expression and tumor
size (P = 0.011), lymph node status (P = 0.001), and recur-
rence (P = 0.002) was statistically significant, supporting
the conclusion that syntenin is involved in breast cancer
progression and metastasis. However, syntenin expression
had no relation with ages, grade, human epidermal growth
factor receptor-2 (Her-2), estrogen receptor (ER), and pro-
gesterone receptor (PR) status (P > 0.05).
To assess whether syntenin is a prognostic indicator for
breast cancer patients, we plotted Kaplan-Meier survival
curves and conducted log-rank tests for overall survival
(OS) and disease-free survival (DFS). The results indi-
cated that the expression level of syntenin was correlated
with OS (P = 0.023; Figure 5B) and DFS (P = 0.001;
Figure 5C). Further to investigate whether syntenin is an
independent prognostic factor, we performed multivari-
ate analysis with the Cox proportional hazards model.
The results showed that syntenin status was an indepen-
dent prognostic factor for OS (hazard ratio (HR): 2.031
(95% CI, 1.002 to 4.117); P = 0.049, Table 2] and DFS
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Figure 4 Activation of integrin b1 and ERK1/2 is essential for syntenin-induced migration and invasion. (A) Silencing of syntenin in
MDA-MB-231HM cells inhibited active integrin b1 expression and phosphorylation of ERK1/2, but had no effects on JNK and p38.
(B) Overexpression of syntenin increased active integrin b1 expression and ERK1/2 phosphorylation in 231-SYN cells. The activation of ERK1/2
was analyzed with Western blot by using phosphor-specific antibodies. (C) Integrin b1 functional blocking antibody blocked both active integrin
b1 expression and ERK1/2 phosphorylation. Cells were treated with integrin b1 or nonspecific IgG for 1 hour before protein extraction. (D) ERK1/
2 inhibitor U0126 blocked activation of ERK1/2. Cells were pretreated with dimethylsulfoxide (DMSO) or 20 µM U0126 (U0126) for 2 hours before
protein extraction. (E, F) U0126 effectively reduced the migration and invasion of breast cancer cells. GAPDH was used as loading control. Data
are expressed as means of triplicate samples from three independent experiments; bars, SD. **P < 0.01; ***P < 0.001.
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Figure 5 Elevated expression of syntenin correlates with poor patient survival . (A) Representative images of syntenin
immunohistochemistry (IHC) staining. a: Negative control consisted of phosphate-buffered saline instead of syntenin antibody. b-f: IHC staining
of paraffin-embedded tumors formed by 231-VEC (b), 231-SYN (c), 231HM-VEC (d), 231HM-262 (e), and 231HM-622 (f) cells. g-i: Representative
images of paracarcinoma (g) and carcinoma (h: negative, i: positive). (B, C) Kaplan-Meier survival analyses of breast cancer patients. (B) OS (P =
0.023). (C) DFS (P = 0.001). P values were calculated by using the log-rank test.
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[HR: 2.281(95% CI 1.355 to 3.841), P = 0.002, Table 3] in
our cohort of patients.
Discussion
In the present study, we provide the first evidence that syn-
tenin expression is upregulated in breast carcinoma, and
the elevated expression of syntenin confers a high risk of
recurrence. In addition, our results suggest a role of synte-
nin overexpression in promoting tumor growth and meta-
static spreading in breast carcinoma. Recently, observations
indicated that syntenin is upregulated in several cancer
cells and tissues and may regulate tumor cell invasion and
metastasis, including gastric carcinomas [12], melanoma
[14,20,21], and brain cancer [22]. Our results were consis-
tent with those previous findings.
Cell migration and invasion are important steps of
tumor metastasis. Metastasis is a complex multistep, and
multigenic regulated process, in which tumor cells alter
its cell-cell adhesion, interact with and break down the
surrounding extracellular matrix or the basement mem-
brane, and migrate through the remodeled ECM to reach
adjacent organs in response to chemoattractants [13]. In
our study, we found that syntenin overexpression could
promote breast cell migration and invasion in vitro, but
the fold changes in migration assay and invasion assay
were similar. It suggests that the major role of syntenin
maybe in cell migration, not in ECM degradation. More-
over, syntenin overexpression did not alter the expression
of matrix metalloproteinases such as MMP-2 and -9, or
their proteolytic activities, as assessed by gelatin zymogra-
phy, which supports that syntenin promotes metastasis of
cancer cells mainly through increasing their migratory
activity [12]. Syntenin could remodel the actin cytoskele-
ton, induce the formation of a variety of plasma mem-
brane structures, including goffer, lamellipodia, exosomes,
and neurite-like structures in neurons and different types
of tumor cells, also indicating that it may play a role in
tumor cell migration [23-26]. Orthotropic xenograft
tumor models in nude mice further supported that synte-
nin could accelerate metastasis in vivo. These results sug-
gest that syntenin play an important role in tumor lung
metastasis.
Although the role of syntenin in regulating cell migra-
tion, invasion, and metastasis has been confirmed by mul-
tiple studies, several discrepant findings have been
observed. Studies in HEK 293T cells revealed the impor-
tance of both PDZ domains in conferring syntenin func-
tion, whereas in breast cancer cells, only the PDZ2
domain has been shown to be relevant [12,13]. In the con-
text of melanoma, syntenin functions as a positive regula-
tor of melanoma progression and metastasis through
interaction with c-Src and promotes the formation of an
active FAK/c-Src signaling complex, leading to activation
of NF-kappa B and subsequent induction of genes
involved in migration and invasion [27]. The activation of
p38 and JNK MAPK plays an important role in syntenin-
mediated anchorage-independent growth and motility in
melanoma [3]. However, Ras, Rho-Rac, PI3K/AKT, and
ERK MAPK signaling were shown to mediate syntenin
function in HEK293T cells [3,13,15,28]. Inhibition of p38
or JNK MAPK did not have any effect on syntenin-
induced invasion in HEK293T cells [13]. In our study, we
found that syntenin-mediated migration and invasion of
breast cancer cells required the activation of integrin
b1and ERK1/2 MAPK. This discrepancy may be explained
by the cell type studied and different environmental con-
texts. The diversity of syntenin-interaction partners also
suggests that syntenin may have flexible cell-type-specific
roles.
Four dominating MAPK signaling pathways are found in
breast disease and function in mammary epithelial cells,
including ERK1/2 pathway, JNK pathway, p38 pathway,
and ERK5 pathway [29,30]. The ERK1/2 pathway has been
shown to promote cell motility and invasion [31], and is
implicated in a number of human breast cancer and in
many experimental models of breast cancer progression
Table 2 Multivariate analysis of overall survival by Cox proportional hazards models
Patients P Hazard ratio (95% confidence interval)
Tumor size T1 versus T2 versus T3 0.076 –
Grade, I versus II versus III 0.769 –
Lymph node status, negative versus positive 0.381 –
Syntenin, negative versus positive 0.049 2.031 (1.002-4.117)
Table 3 Multivariate analysis of disease-free survival by Cox proportional hazards models
Patients P Hazard ratio (95% confidence interval)
Tumor size T1 versus T2 versus T3 0.77 –
Grade, I versus II versus III 0.326 –
Lymph node status, negative versus positive 1.356 –
Syntenin, negative versus positive 0.002 2.281 (1.355-3.841)
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[30]. Because syntenin overexpression increased the phos-
phorylation level of ERK1/2, we believe that ERK1/2 might
modulate the increased migration and invasion of breast
cancer cells. Inhibition of ERK1/2 activation with U0126
significantly reduced both expression of phosphorylated
ERK1/2 and syntenin-induced migration and invasion.
These data revealed an essential role for the ERK1/2 sig-
naling pathway in syntenin-induced migration and inva-
sion in breast cancer cells.
We further investigated how syntenin activates ERK1/
2 at the plasma membrane, and found that integrin b1
was involved in syntenin-induced ERK1/2 activation.
Taken together, these results suggest that syntenin
could activate ERK1/2 through an integrin/RAS/RAF/
MEK/ERK signaling pathway, and ERK1/2 activation
was essential for syntenin-induced migration and inva-
sion in breast cancer cells.
Although syntenin overexpression had no effect on cell
proliferation in vitro, it promoted tumor growth in vivo. It
might be ascribed to angiogenesis regulated by syntenin
overexpression. Angiogenesis is a complex process that
appears to be important for tumor growth and metastatic
potential [32]. A recent study demonstrated that syntenin
is a key regulator of angiogenesis and regulates the expres-
sion of several proteins responsible for promoting angio-
genesis, including insulin growth factor binding protein-2
(IGFBP-2) and interleukin-8 [33]. Moreover, several stu-
dies have shown that ERK activation is involved in angio-
genesis [34-36]. In our study, we found that syntenin
overexpression could induce both ERK activation and
angiogenesis in breast cancer. Therefore, it is reasonable
for us to believe that the ERK MAPK pathway may be
involved in syntenin-induced angiogenesis.
More important, we performed IHC staining on human
breast cancer samples. In our 239-case study, we found a
significant correlation between syntenin expression level
and tumor size, lymph node status, and recurrence. The
correlation between syntenin expression and metastasis
was consistent with our in vivo and vitro experiments.
The Kaplan-Meier survival analysis showed that syntenin
expression was correlated with OS and DFS. In multivari-
ate analysis with Cox proportional hazards model, we
found syntenin status was an independent prognostic fac-
tor for OS and DFS in breast cancer patients. These results
further supported that syntenin is involved in breast can-
cer progression and positively correlated with metastasis.
In conclusion, our present data indicate that syntenin
plays an important role in breast cancer metastasis and
progression both in vitro and in vivo. The expression level
of syntenin is positively correlated with patient survival.
These findings suggest that syntenin deserves further
investigation as a potential target for novel therapies aim-
ing to block the metastatic process in this tumor.
Conclusions
Our study shows that syntenin expression is upregulated
in high-metastasis breast cancer cell lines and breast
cancer tissues. Syntenin overexpression promotes breast
cancer cell migration and invasion in vitro. Moreover,
syntenin overexpression promotes breast tumor growth
and lung metastasis in vivo. Activation of integrin b1
and ERK1/2 are essential for syntenin-induced migration
and invasion in vitro. The correlation between syntenin
expression and tumor size, lymph node status, and
recurrence is statistically significant. The expression
level of syntenin in breast cancer tissues was signifi-
cantly correlated with OS and DFS in our cohort of
patients. These results suggest that syntenin plays a sig-
nificant role in breast cancer progression and is posi-
tively correlated with metastasis.
Additional material
Additional file 1: Figure S1 Comparison of syntenin protein
expression in the rest of 15 paired carcinomas (CARs) and
paracarcinomas (PARA-CARs). Protein loading was normalized to
GAPDH. Figure S2 Lentivirus-mediated syntenin expression changes in
breast cancer cell lines. (A, B) Syntenin overexpression in MDA-MB-231
cells was detected with real-time PCR and Western blot. (C, D) Real-time
PCR and Western blot analysis of syntenin knockdown in MDA-MB-
231HM cells. Relative mRNA levels were normalized to GAPDH mRNA.
Protein loading was normalized to GAPDH. Columns, mean of three
independent experiments; bars, SD.
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